Thursday, September 8, 2011

Theraclone Sciences Snags $10.6M More In Series B

Seattle-based Theraclone Sciences, a biotechnology firm focused on developing therapeutic antibodies for treating infectious disease and cancer, said Thursday that it has raised $10.6M in a Series B funding round. The round came from prior investors ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo. The company said the new funding brings its Series B to $41M. The funding will go towards its clinical programs and discovery projects. Theraclone Sciences is headed by Steven Gillis. More information »